Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis

Biochemical and Biophysical Research Communications

Volumn 497, Issue 1, 2018, Pages 207-213

  Amano, Yuichiro ^a   Tsuchiya, Shuntarou ^a,b   Imai, Mayumi ^a   Tohyama, Kimio ^a   Matsukawa, Jun ^a   Isono, Osamu ^a   Yasuno, Hironobu ^a   Enya, Kazuaki ^a   Koumura, Emiko ^a   Nagabukuro, Hiroshi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b Axcelead Drug Discovery Partners   (Japan)

Author keywords

Alogliptin; Combination therapy; Hepatic fibrosis; Nonalcoholic steatohepatitis; Pioglitazone

Indexed keywords

ALOGLIPTIN; CD11B ANTIGEN; COLLAGEN TYPE 1; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PIPERIDINE DERIVATIVE; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIMETABOLIC ACTIVITY; ARTICLE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; KNOCKOUT MOUSE; LIVER FIBROSIS; MALE; MONOTHERAPY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANIMAL; DRUG COMBINATION; DRUG EFFECTS; LIVER; LIVER CIRRHOSIS; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HYPOGLYCEMIC AGENTS; LIVER; LIVER CIRRHOSIS; MICE; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; PIPERIDINES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; URACIL;

EID: 85041905374     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2018.02.055     Document Type: Article

References (32)

1. Leite, N.C., Salles, G.F., Araujo, A.L., Villela-Nogueira, C.A., Cardoso, C.R., Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 29 (2009), 113–119.
2. Jimba, S., Nakagami, T., Takahashi, M., et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 22 (2005), 1141–1145.
3. Hotta, N., Nakamura, J., Iwamoto, Y., et al. Causes of death in Japanese diabetics: a questionnaire survey of 18,385 diabetics over a 10-year period. J. Diabetes Investig. 1 (2010), 66–76.
4. Boettcher, E., Csako, G., Pucino, F., Wesley, R., Loomba, R., Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 35 (2012), 66–75.
5. Uchimura, K., Nakamuta, M., Enjoji, M., et al. Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology 33 (2001), 91–99.
6. Aoki, Y., Maeno, T., Aoyagi, K., et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration 77 (2009), 311–319.
7. Zafiriou, S., Stanners, S.R., Saad, S., Polhill, T.S., Poronnik, P., Pollock, C.A., Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J. Am. Soc. Nephrol. 16 (2005), 638–645.
8. Yilmaz, Y., Yonal, O., Deyneli, O., Celikel, C.A., Kalayci, C., Duman, D.G., Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol. Belg. 75 (2012), 240–244.
9. Kato, H., Nagai, Y., Ohta, A., et al. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 109 (2015), 199–205.
10. Mashitani, T., Noguchi, R., Okura, Y., et al. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed. Rep. 4 (2016), 183–187.
11. Jung, Y.A., Choi, Y.K., Jung, G.S., et al. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. Diabetes Res. Clin. Pract. 105 (2014), 47–57.
12. Fukuda-Tsuru, S., Kakimoto, T., Utsumi, H., Kiuchi, S., Ishii, S., The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Eur. J. Pharmacol. 723 (2014), 207–215.
13. Kern, M., Kloting, N., Niessen, H.G., et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One, 7, 2012, e38744.
14. Klein, T., Fujii, M., Sandel, J., et al. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Med. Mol. Morphol. 47 (2014), 137–149.
15. Ideta, T., Shirakami, Y., Miyazaki, T., et al. The dipeptidyl Peptidase-4 inhibitor teneligliptin attenuates hepatic lipogenesis via AMPK activation in non-alcoholic fatty liver disease model mice. Int. J. Mol. Sci. 16 (2015), 29207–29218.
16. Craddy, P., Palin, H.J., Johnson, K.I., Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 5 (2014), 1–41.
17. Kaku, K., Katou, M., Igeta, M., Ohira, T., Sano, H., Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study. Diabetes Obes. Metab. 17 (2015), 1198–1201.
18. Amano, Y., Shimizu, F., Yasuno, H., et al. Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge. Hepatol. Res. 47 (2017), 103–115.
19. Moritoh, Y., Takeuchi, K., Hazama, M., Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J. Pharmacol. Exp. Ther. 329 (2009), 669–676.
20. Tsuchiya, S., Amano, Y., Isono, O., et al. Pharmacological evaluation of pioglitazone and candesartan cilexetil in a novel mouse model of non-alcoholic steatohepatitis, modified choline-deficient, amino acid-defined diet fed low-density lipoprotein receptor knockout mice. Hepatol. Res. 47 (2017), 584–592.
21. Moritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., Odaka, H., The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur. J. Pharmacol. 602 (2009), 448–454.
22. Moritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., Odaka, H., Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br. J. Pharmacol. 157 (2009), 415–426.
23. Da Silva Morais, A., Lebrun, V., Abarca-Quinones, J., et al. Prevention of steatohepatitis by pioglitazone: implication of adiponectin-dependent inhibition of SREBP-1c and inflammation. J. Hepatol. 50 (2009), 489–500.
24. Lefebvre, E., Moyle, G., Reshef, R., et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One, 11, 2016, e0158156.
25. Marra, F., Tacke, F., Roles for chemokines in liver disease. Gastroenterology 147 (2014), 577–594 e1.
26. Haukeland, J.W., Damas, J.K., Konopski, Z., et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 44 (2006), 1167–1174.
27. Miura, K., Yang, L., van Rooijen, N., Ohnishi, H., Seki, E., Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am. J. Physiol. Gastrointest. Liver Physiol. 302 (2012), G1310–G1321.
28. Wang, X., Hausding, M., Weng, S.Y., et al. Gliptins suppress inflammatory macrophage activation to mitigate inflammation, fibrosis, oxidative stress, and vascular dysfunction in models of nonalcoholic steatohepatitis and liver fibrosis. Antioxid. Redox Signal 28 (2018), 87–109.
29. Itou, M., Kawaguchi, T., Taniguchi, E., Sata, M., Dipeptidyl peptidase-4: a key player in chronic liver disease. World J. Gastroenterol. 19 (2013), 2298–2306.
30. Rull, A., Rodriguez, F., Aragones, G., et al. Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis. Cytokine 48 (2009), 273–279.
31. Leclercq, I.A., Lebrun, V.A., Starkel, P., Horsmans, Y.J., Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. Lab. Invest. 87 (2007), 56–65.
32. Moran-Salvador, E., Titos, E., Rius, B., et al. Cell-specific PPARgamma deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. J. Hepatol. 59 (2013), 1045–1053.